| Year |
Title |
Altmetric |
| 2023
|
2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases.
Arthritis Care and Research.
75:449-464.
2023
|
|
| 2023
|
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: Results from the open-label, randomised controlled ORAL Surveillance trial.
Annals of the Rheumatic Diseases.
82:331-343.
2023
|
|
| 2023
|
Commentary on Cohen et al.: Role of Clinical Factors in Precision Medicine Test to Predict Nonresponse to TNFi Therapies in Rheumatoid Arthritis.
Rheumatology and Therapy.
10:1-6.
2023
|
|
| 2023
|
Identification of Multimorbidity Patterns in Rheumatoid Arthritis Through Machine Learning.
Arthritis Care and Research.
75:220-230.
2023
|
|
| 2023
|
Incidence of Herpes Zoster in Patients With Rheumatoid Arthritis in the United States: A Retrospective Cohort Study..
Journal of Rheumatology.
2023
|
|
| 2023
|
Influence of Multimorbidity on New Treatment Initiation and Achieving Target Disease Activity Thresholds in Active Rheumatoid Arthritis: A Cohort Study Using the Rheumatology Informatics System for Effectiveness Registry.
Arthritis Care and Research.
75:231-239.
2023
|
|
| 2023
|
2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases.
Arthritis and Rheumatology.
2023
|
|
| 2023
|
American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 5.
Arthritis and Rheumatology.
75:E1-E16.
2023
|
|
| 2023
|
Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 weeks: An Indirect Treatment Comparison.
Rheumatology and Therapy.
2023
|
|
| 2023
|
Effects of Disease-Worsening Following Withdrawal of Etanercept or Methotrexate on Patient-Reported Outcomes in Patients With Rheumatoid Arthritis: Results From the SEAM-RA Trial
2023
|
|
| 2023
|
Geographic Variation in Disease Burden and Mismatch in Care of Patients With Rheumatoid Arthritis in the United States.
ACR Open Rheumatology.
2023
|
|
| 2023
|
Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study.
Rheumatology and Therapy.
2023
|
|
| 2022
|
Reply to letter to the editor from Dr. Boers re: Rheumatoid arthritis disease activity and hospitalized infection in a large U.S. registry..
Arthritis Care and Research.
2022
|
|
| 2022
|
Adherence patterns in naïve and prevalent use of infliximab and its biosimilar.
BMC Rheumatology.
6.
2022
|
|
| 2022
|
Comparing cardiovascular risk of patients with rheumatoid arthritis within the Social Security Disability Insurance with those commercially insured.
Arthritis Research and Therapy.
24.
2022
|
|
| 2022
|
Incidence of dementia in patients with rheumatoid arthritis and association with disease modifying anti-rheumatic drugs – Analysis of a national claims database.
Seminars in Arthritis and Rheumatism.
57.
2022
|
|
| 2022
|
Machine Learning Applied to Patient-Reported Outcomes to Classify Physician-Derived Measures of Rheumatoid Arthritis Disease Activity.
ACR Open Rheumatology.
4:995-1003.
2022
|
|
| 2022
|
Protocol for the pilot randomized trial of the CArdiovascular Risk assEssment for Rheumatoid Arthritis (CARE RA) intervention: a peer coach behavioral intervention.
Pilot and Feasibility Studies.
8.
2022
|
|
| 2022
|
Validation of an algorithm to identify incident interstitial lung disease in patients with rheumatoid arthritis.
Arthritis Research and Therapy.
24.
2022
|
|
| 2022
|
Recombinant Zoster Vaccine Uptake and Risk of Flares Among Older Adults With Immune-Mediated Inflammatory Diseases in the US.
Arthritis and Rheumatology.
74:1833-1841.
2022
|
|
| 2022
|
Satisfaction with modes of telemedicine delivery during COVID-19: A randomized, single-blind, parallel group, noninferiority trial.
American Journal of the Medical Sciences.
364:538-546.
2022
|
|
| 2022
|
The Economic Benefit of Remission for Patients with Rheumatoid Arthritis.
Rheumatology and Therapy.
9:1329-1345.
2022
|
|
| 2022
|
The Effect of Guselkumab on General Health State in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial.
Advances in Therapy.
39:4632-4644.
2022
|
|
| 2022
|
The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial.
Advances in Therapy.
39:4613-4631.
2022
|
|
| 2022
|
Complement activation products vs standard ANA testing: Treatment outcomes, diagnosis, and economic impact (CAPSTONE) in systemic lupus erythematosus.
Journal of managed care & specialty pharmacy.
28:1021-1032.
2022
|
|
| 2022
|
Identifying inadequate response among patients with ankylosing spondylitis and psoriatic arthritis prescribed advanced therapy in a real-world, commercially insured adult population in the USA.
Clinical Rheumatology.
41:2863-2874.
2022
|
|
| 2022
|
Rheumatologist and Patient Mental Models for Treatment of Rheumatoid Arthritis Help Explain Low Treat-to-Target Rates.
ACR Open Rheumatology.
4:700-710.
2022
|
|
| 2022
|
Association between chronic obstructive pulmonary disease, smoking, and interstitial lung disease onset in rheumatoid arthritis.
Clinical and Experimental Rheumatology.
40:1280-1284.
2022
|
|
| 2022
|
Impact of Methotrexate Discontinuation, Interruption, or Persistence in US Patients with Rheumatoid Arthritis Initiating Tofacitinib + Oral Methotrexate Combination
2022
|
|
| 2022
|
Patient Perceptions and Preferences Regarding Telemedicine for Autoimmune Rheumatic Diseases Care During the COVID-19 Pandemic.
Arthritis Care and Research.
74:1049-1057.
2022
|
|
| 2022
|
COVID-19 Update for the GRAPPA 2021 Annual Meeting: Focus on COVID-19 Vaccination.
Journal of Rheumatology.
49:10-12.
2022
|
|
| 2022
|
COVID-19 vaccine uptake and vaccine hesitancy in rheumatic disease patients receiving immunomodulatory therapies in community practice settings.
Arthritis and Rheumatology.
74:1091-1092.
2022
|
|
| 2022
|
American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 4.
Arthritis and Rheumatology.
74:21-e36.
2022
|
|
| 2022
|
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies.
RMD Open.
8.
2022
|
|
| 2022
|
Medication Interruptions and Subsequent Disease Flares During the COVID-19 Pandemic: A Longitudinal Online Study of Patients With Rheumatic Disease.
Arthritis Care and Research.
74:733-740.
2022
|
|
| 2022
|
Primary Prophylaxis for Pneumocystis jirovecii Pneumonia in Patients Receiving Rituximab.
Chest.
161:1201-1210.
2022
|
|
| 2022
|
Employment, Work Productivity, and Biologic Treatments in Self-Reported Axial Spondyloarthritis: a Cross-Sectional Study in a Female Predominant Population from the ArthritisPower Registry.
Rheumatology and Therapy.
9:663-677.
2022
|
|
| 2022
|
Evaluation of an Intervention to Support Patient-Rheumatologist Conversations About Escalating Treatment in Patients with Rheumatoid Arthritis: A Proof-of-Principle Study.
ACR Open Rheumatology.
4:279-287.
2022
|
|
| 2022
|
Identifying Minimal and Meaningful Change in a Patient-Reported Outcomes Measurement Information System for Rheumatoid Arthritis: Use of Multiple Methods and Perspectives.
Arthritis Care and Research.
74:588-597.
2022
|
|
| 2022
|
Patient Perspectives on Biologics for Axial Spondyloarthritis in a Cross-sectional Study in a Predominantly Female Population: Treatment Satisfaction, Wear-off Between Doses, and Use of Supplemental Medication.
Rheumatology and Therapy.
9:509-520.
2022
|
|
| 2022
|
Prevalence of Frailty in Ankylosing Spondylitis, Psoriatic Arthritis, and Rheumatoid Arthritis: Data from a National Claims Dataset.
ACR Open Rheumatology.
4:300-305.
2022
|
|
| 2022
|
Characteristics, Comorbidities, and Outcomes of SARS-CoV-2 Infection in Patients With Autoimmune Conditions Treated With Systemic Therapies: A Population-based Study.
Journal of Rheumatology.
49:320-329.
2022
|
|
| 2022
|
Pain Reduction in Rheumatoid Arthritis Patients Who Use Opioids: A Post Hoc Analysis of Phase 3 Trials of Baricitinib.
ACR Open Rheumatology.
4:254-258.
2022
|
|
| 2022
|
Activated Peripheral Blood B Cells in Rheumatoid Arthritis and Their Relationship to Anti–Tumor Necrosis Factor Treatment and Response: A Randomized Clinical Trial of the Effects of Anti–Tumor Necrosis Factor on B Cells.
Arthritis and Rheumatology.
74:200-211.
2022
|
|
| 2022
|
Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment.
Rheumatology and Therapy.
9:243-263.
2022
|
|
| 2022
|
Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials.
Annals of the Rheumatic Diseases.
81:206-213.
2022
|
|
| 2022
|
Patient-Reported Nausea and Fatigue Related to Methotrexate: A Prospective, Self-Controlled Study in the ArthritisPower® Registry.
Rheumatology and Therapy.
9:207-221.
2022
|
|
| 2022
|
Childhood-onset lupus nephritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: Short-term kidney status and variation in care.
Arthritis Care and Research.
2022
|
|
| 2022
|
Clinical utility of therapy selection informed by predicted nonresponse to tumor necrosis factor-ɑ inhibitors: an analysis from the Study to Accelerate Information of Molecular Signatures (AIMS) in rheumatoid arthritis
2022
|
|
| 2022
|
Comparative safety of inhaled corticosteroids and macrolides in Medicare enrolees with bronchiectasis.
ERJ Open Research.
8.
2022
|
|
| 2022
|
EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: The November 2021 update.
Annals of the Rheumatic Diseases.
2022
|
|
| 2022
|
Enhancing Patient Understanding of Medication Risks and Benefits.
Arthritis Care and Research.
74:142-150.
2022
|
|
| 2022
|
Patient outcomes improve when a molecular signature test guides treatment decision-making in rheumatoid arthritis
2022
|
|
| 2022
|
Prevention and management of herpes zoster in patients with rheumatoid arthritis and psoriatic arthritis: a clinical review.
Clinical and Experimental Rheumatology.
40:162-172.
2022
|
|
| 2022
|
Rheumatoid arthritis disease activity and hospitalized infection in a large U.S. registry.
Arthritis Care and Research.
2022
|
|
| 2022
|
Risk of serious infection with low-dose Glucocorticoids in patients with rheumatoid arthritis.
Epidemiology.
33:65-74.
2022
|
|
| 2022
|
TNFi Cycling Versus Changing Mechanism of Action in TNFi-Experienced Patients: Result of the Corrona CERTAIN Comparative Effectiveness Study.
ACR Open Rheumatology.
4:65-73.
2022
|
|
| 2022
|
Treatment Satisfaction and Decision-making from the Patient Perspective in Axial Spondyloarthritis: Real-World Data from a Descriptive Cross-sectional Survey Study from the ArthritisPower Registry.
ACR Open Rheumatology.
4:85-94.
2022
|
|
| 2022
|
Understanding Physicians’ Perceptions of Patient-Identified Barriers to Osteoporosis Medication Initiation: A Cognitive Mapping Approach.
Risk Management and Healthcare Policy.
15:1293-1302.
2022
|
|
| 2021
|
Correction to: Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data (Rheumatology and Therapy, (2021), 8, 4, (1661-1675), 10.1007/s40744-021-00361-5).
Rheumatology and Therapy.
8:1921-1922.
2021
|
|
| 2021
|
Development and validation of the Methotrexate Experience Questionnaire, a new methotrexate oral treatment adherence tool in rheumatoid arthritis.
Journal of Patient-Reported Outcomes.
5.
2021
|
|
| 2021
|
Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data.
Rheumatology and Therapy.
8:1661-1675.
2021
|
|
| 2021
|
Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study.
Rheumatology and Therapy.
8:1551-1563.
2021
|
|
| 2021
|
Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis.
Annals of the Rheumatic Diseases.
80:1522-1529.
2021
|
|
| 2021
|
Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies.
Arthritis Research and Therapy.
23.
2021
|
|
| 2021
|
Which patient-reported outcomes do rheumatology patients find important to track digitally? A real-world longitudinal study in ArthritisPower.
Arthritis Research and Therapy.
23.
2021
|
|
| 2021
|
Higher Serum Urate Levels Are Associated With an Increased Risk for Sudden Cardiac Death.
Journal of Rheumatology.
48:1745-1753.
2021
|
|
| 2021
|
Patient-Powered Research Networks of the Autoimmune Research Collaborative: Rationale, Capacity, and Future Directions
2021
|
|
| 2021
|
Systematic Literature Review of Residual Symptoms and an Unmet Need in Patients With Rheumatoid Arthritis.
Arthritis Care and Research.
73:1606-1616.
2021
|
|
| 2021
|
The Annual Diagnostic Prevalence of Ankylosing Spondylitis and Axial Spondyloarthritis in the United States Using Medicare and MarketScan Databases.
ACR Open Rheumatology.
3:743-752.
2021
|
|
| 2021
|
The safety and immunologic effectiveness of the live varicella-zoster vaccine in patients receiving tumor necrosis factor inhibitor therapy a randomized controlled trial.
ACP journal club.
174:1510-1518.
2021
|
|
| 2021
|
Tumor necrosis factor inhibitors and the risk of cancer among older Americans with rheumatoid arthritis.
Cancer Epidemiology, Biomarkers and Prevention.
30:2059-2067.
2021
|
|
| 2021
|
Variability in Glucocorticoid Prescribing for Rheumatoid Arthritis and the Influence of Provider Preference on Long-Term Use of Glucocorticoids.
Arthritis Care and Research.
73:1597-1605.
2021
|
|
| 2021
|
American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3.
Arthritis and Rheumatology.
73:e60-e75.
2021
|
|
| 2021
|
Effects of the SARS-CoV-2 global pandemic on U.S. rheumatology outpatient care delivery and use of telemedicine: an analysis of data from the RISE registry
2021
|
|
| 2021
|
Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases.
Annals of the Rheumatic Diseases.
80:1255-1265.
2021
|
|
| 2021
|
A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study.
Rheumatology and Therapy.
8:1159-1176.
2021
|
|
| 2021
|
A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease.
Gastroenterology.
161:837-852.e9.
2021
|
|
| 2021
|
Prevalence of Renal Impairment in a US Commercially Insured Rheumatoid Arthritis Population: A Retrospective Analysis.
Rheumatology and Therapy.
8:1383-1391.
2021
|
|
| 2021
|
Reply.
Arthritis and Rheumatology.
73:1771-1772.
2021
|
|
| 2021
|
Reply.
Arthritis and Rheumatology.
73:1769-1770.
2021
|
|
| 2021
|
Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data from the IBM MarketScan® Administrative Claims Database with Tofacitinib Trial Data.
Inflammatory Bowel Diseases.
27:1394-1408.
2021
|
|
| 2021
|
American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2..
Arthritis and Rheumatology.
73:e30-e45.
2021
|
|
| 2021
|
Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index.
ACR Open Rheumatology.
3:501-511.
2021
|
|
| 2021
|
Disruptions in Rheumatology Care and the Rise of Telehealth in Response to the COVID-19 Pandemic in a Community Practice–Based Network.
Arthritis Care and Research.
73:1153-1161.
2021
|
|
| 2021
|
Meaningful change thresholds for patient-reported outcomes measurement information system (PROMIS) fatigue and pain interference scores in patients with rheumatoid arthritis.
Journal of Rheumatology.
48:1239-1242.
2021
|
|
| 2021
|
Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
Arthritis Care and Research.
73:1114-1124.
2021
|
|
| 2021
|
American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1.
Arthritis and Rheumatology.
73:1093-1107.
2021
|
|
| 2021
|
Anca-Associated vasculitis management in the united states: Data from the rheumatology informatics system for effectiveness (rise) registry.
Journal of Rheumatology.
48:1060-1064.
2021
|
|
| 2021
|
Economic Burden of Osteoporosis-Related Fractures in the US Medicare Population.
Annals of Pharmacotherapy.
55:821-829.
2021
|
|
| 2021
|
Evaluation of the Effect of Diabetes on Rheumatoid Arthritis-related Outcomes in an Electronic Health Record-based Rheumatology Registry.
Journal of Rheumatology.
48:992-1001.
2021
|
|
| 2021
|
Tough Choices: Exploring Medication Decision-Making During Pregnancy and Lactation Among Women With Inflammatory Arthritis.
ACR Open Rheumatology.
3:475-483.
2021
|
|
| 2021
|
Benefits of methotrexate use on cardiovascular disease risk among rheumatoid arthritis patients initiating biologic disease-modifying antirheumatic drugs.
Journal of Rheumatology.
48:804-812.
2021
|
|
| 2021
|
Evaluation of the impact of age and adiposity on a multi-biomarker disease activity score before and after adjustment.
Clinical Rheumatology.
40:2419-2426.
2021
|
|
| 2021
|
Social Distancing, Health Care Disruptions, Telemedicine Use, and Treatment Interruption During the COVID-19 Pandemic in Patients With or Without Autoimmune Rheumatic Disease.
ACR Open Rheumatology.
3:381-389.
2021
|
|
| 2021
|
Treatment Strategies for Patients with Immune-Mediated Inflammatory Diseases.
Journal of the American Medical Association.
325:1726-1728.
2021
|
|
| 2021
|
Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission.
Arthritis and Rheumatology.
73:759-768.
2021
|
|
| 2021
|
Comparative effectiveness of biologics and targeted therapies for psoriatic arthritis.
RMD Open.
7.
2021
|
|
| 2021
|
Concerns, healthcare use, and treatment interruptions in patients with common autoimmune rheumatic diseases during the COVID-19 pandemic.
Journal of Rheumatology.
48:603-607.
2021
|
|
| 2021
|
Data-Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women’s Rheumatoid Arthritis Sequential Study Registry.
Arthritis Care and Research.
73:471-480.
2021
|
|
| 2021
|
ArthritisPower Reflects Optimal Characteristics of Apps for Rheumatoid Arthritis
2021
|
|
| 2021
|
Assessing rheumatologists’ attitudes and utilization of classification criteria for ankylosing spondylitis and axial spondyloarthritis: a global effort.
Clinical Rheumatology.
40:949-954.
2021
|
|
| 2021
|
Burden and trajectory of multimorbidity in rheumatoid arthritis: A matched cohort study from 2006 to 2015.
Annals of the Rheumatic Diseases.
80:286-292.
2021
|
|
| 2021
|
Oral Glucocorticoids and Incident Treatment of Diabetes Mellitus, Hypertension, and Venous Thromboembolism in Children.
American Journal of Epidemiology.
190:403-412.
2021
|
|
| 2021
|
Association of cardiovascular disease and traditional cardiovascular risk factors with the incidence of dementia among patients with rheumatoid arthritis.
Seminars in Arthritis and Rheumatism.
51:292-298.
2021
|
|
| 2021
|
Associations between an expanded autoantibody profile and treatment responses to biologic therapies in patients with rheumatoid arthritis.
International Immunopharmacology.
91.
2021
|
|
| 2021
|
Low Incidence of Inflammatory Bowel Disease Adverse Events in Adalimumab Clinical Trials Across Nine Different Diseases.
Arthritis Care and Research.
73:289-295.
2021
|
|
| 2021
|
SARS CoV-2 infection among patients using immunomodulatory therapies.
Annals of the Rheumatic Diseases.
80:269-271.
2021
|
|
| 2021
|
Case Fatality Rates for Patients with COVID-19 Requiring Invasive Mechanical Ventilation.
American Journal of Respiratory and Critical Care Medicine.
203:54-66.
2021
|
|
| 2021
|
Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activity.
PLoS One.
16.
2021
|
|
| 2021
|
Effects of the COVID-19 Pandemic on Patients Living With Vasculitis.
ACR Open Rheumatology.
3:17-24.
2021
|
|
| 2020
|
Antiphospholipid Antibody Testing in a General Population Sample from the USA: An Administrative Database Study.
Scientific Reports.
10.
2020
|
|
| 2020
|
Change in inappropriate critical care over time.
Journal of Critical Care.
60:267-272.
2020
|
|
| 2020
|
Circulating microbial small RNAs are altered in patients with rheumatoid arthritis.
Annals of the Rheumatic Diseases.
79:1557-1564.
2020
|
|
| 2020
|
Derivation and internal validation of a multi-biomarker-based cardiovascular disease risk prediction score for rheumatoid arthritis patients.
Arthritis Research and Therapy.
22.
2020
|
|
| 2020
|
Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients.
Scientific Reports.
10.
2020
|
|
| 2020
|
Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis : A Cohort Study.
ACP journal club.
173:870-878.
2020
|
|
| 2020
|
Risk-benefit analysis of isoniazid monotherapy to prevent tuberculosis in patients with rheumatic diseases exposed to prolonged, high-dose glucocorticoids.
PLoS One.
15.
2020
|
|
| 2020
|
Trends in Hospitalization Rates, Major Causes of Hospitalization, and In-Hospital Mortality in Rheumatoid Arthritis in the United States From 2000 to 2014.
ACR Open Rheumatology.
2:715-724.
2020
|
|
| 2020
|
Use of ICD-10 diagnosis codes to identify seropositive and seronegative rheumatoid arthritis when lab results are not available.
Arthritis Research and Therapy.
22.
2020
|
|
| 2020
|
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Annals of the Rheumatic Diseases.
79:1400-1413.
2020
|
|
| 2020
|
The effect of disease-modifying antirheumatic drugs on vaccine immunogenicity in adults.
Cleveland Clinic Journal of Medicine.
87:695-703.
2020
|
|
| 2020
|
What Does the Patient Global Health Assessment in Rheumatoid Arthritis Really Tell Us? Contribution of Specific Dimensions of Health-Related Quality of Life.
Arthritis Care and Research.
72:1571-1578.
2020
|
|
| 2020
|
Long-term safety of tofacitinib up to 9.5 years: A comprehensive integrated analysis of the rheumatoid arthritis clinical development programme.
RMD Open.
6.
2020
|
|
| 2020
|
Performance of Administrative Algorithms to Identify Interstitial Lung Disease in Rheumatoid Arthritis.
Arthritis Care and Research.
72:1392-1403.
2020
|
|
| 2020
|
Racial and ethnic differences in medication use among beneficiaries of social security disability insurance with rheumatoid arthritis.
Seminars in Arthritis and Rheumatism.
50:988-995.
2020
|
|
| 2020
|
Secular Trends in the Incidence of Hip Fracture Among Nursing Home Residents.
Journal of Bone and Mineral Research.
35:1668-1675.
2020
|
|
| 2020
|
Physical activity measured using wearable activity tracking devices associated with gout flares.
Arthritis Research and Therapy.
22.
2020
|
|
| 2020
|
Racial Disparities Exist in Outcomes After Major Fragility Fractures.
Journal of the American Geriatrics Society.
68:1803-1810.
2020
|
|
| 2020
|
Real-world switch patterns and healthcare costs in biologic-naive psoriasis patients initiating apremilast or biologics.
Journal of Comparative Effectiveness Research.
9:767-779.
2020
|
|
| 2020
|
Using negative control outcomes to assess the comparability of treatment groups among women with osteoporosis in the United States.
Pharmacoepidemiology and Drug Safety.
29:854-863.
2020
|
|
| 2020
|
Trends of lymphoma incidence in US veterans with rheumatoid arthritis, 2002-2017.
RMD Open.
6.
2020
|
|
| 2020
|
Comparative safety of flavocoxid vs prescription NSAIDs among osteoarthritis patients.
Osteoarthritis and Cartilage.
28:917-923.
2020
|
|
| 2020
|
Factors associated with the contemplative stage of readiness to initiate osteoporosis treatment.
Osteoporosis International.
31:1283-1290.
2020
|
|
| 2020
|
Mapping from the International Classification of Diseases (ICD) 9th to 10th Revision for Research in Biologics and Biosimilars Using Administrative Healthcare Data.
Pharmacoepidemiology and Drug Safety.
29:770-777.
2020
|
|
| 2020
|
Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars.
Pharmacoepidemiology and Drug Safety.
29:757-769.
2020
|
|
| 2020
|
Osteoporotic fracture trends in a population of US managed care enrollees from 2007 to 2017.
Osteoporosis International.
31:1299-1304.
2020
|
|
| 2020
|
Patient and Rheumatologist Perspectives Regarding Challenges to Achieving Optimal Disease Control in Rheumatoid Arthritis.
Arthritis Care and Research.
72:933-941.
2020
|
|
| 2020
|
Barriers and facilitators for screening and treatment of hyperlipidemia among patients with inflammatory arthritis.
BMC Rheumatology.
4.
2020
|
|
| 2020
|
Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns for Rheumatoid Arthritis Among United States Physicians.
Rheumatology and Therapy.
7:383-400.
2020
|
|
| 2020
|
Harnessing health plan enrollee data to boost membership in patient-powered research networks.
BMC Health Services Research.
20.
2020
|
|
| 2020
|
Duration of Bisphosphonate Drug Holidays and Associated Fracture Risk.
Medical Care.
58:419-426.
2020
|
|
| 2020
|
Economic burden of osteoporotic fractures in US managed care enrollees.
American Journal of Managed Care.
26:E142-E149.
2020
|
|
| 2020
|
Immunosuppression and the risk of readmission and mortality in patients with rheumatoid arthritis undergoing hip fracture, abdominopelvic and cardiac surgery.
Annals of the Rheumatic Diseases.
79:573.
2020
|
|
| 2020
|
Reply.
Arthritis Care and Research.
72:736-738.
2020
|
|
| 2020
|
Reply to Serious Adverse Events With Romosozumab Use in Japanese Patients: Need for Clear Formulation of Contraindications Worldwide.
Journal of Bone and Mineral Research.
35:996-997.
2020
|
|
| 2020
|
Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
Advances in Therapy.
37:2098-2115.
2020
|
|
| 2020
|
Gout is associated with an increased risk for incident heart failure among older adults: The REasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study.
Arthritis Research and Therapy.
22.
2020
|
|
| 2020
|
An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data.
Drug Safety.
43:379-392.
2020
|
|
| 2020
|
Assessing Rheumatoid Arthritis Disease Activity With Patient-Reported Outcomes Measurement Information System Measures Using Digital Technology.
Arthritis Care and Research.
72:553-560.
2020
|
|
| 2020
|
Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
Arthritis Care and Research.
72:561-576.
2020
|
|
| 2020
|
Incidence of serious infections and design of utilization and safety studies for biologic and biosimilar surveillance.
Journal of managed care & specialty pharmacy.
26:417-490.
2020
|
|
| 2020
|
Patterns of glucocorticoid prescribing and provider-level variation in a commercially insured incident rheumatoid arthritis population: A retrospective cohort study.
Seminars in Arthritis and Rheumatism.
50:228-236.
2020
|
|
| 2020
|
Views of primary care physicians and rheumatologists regarding screening and treatment of hyperlipidemia among patients with rheumatoid arthritis.
BMC Rheumatology.
4.
2020
|
|
| 2020
|
Temporal Trends and Factors Associated with Bisphosphonate Discontinuation and Restart.
Journal of Bone and Mineral Research.
35:478-487.
2020
|
|
| 2020
|
Do Patients With Moderate or High Disease Activity Escalate Rheumatoid Arthritis Therapy According to Treat-to-Target Principles? Results From the Rheumatology Informatics System for Effectiveness Registry of the American College of Rheumatology.
Arthritis Care and Research.
72:166-175.
2020
|
|
| 2020
|
Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices.
ACR Open Rheumatology.
2:79-83.
2020
|
|
| 2020
|
Barriers to treatment optimization and achievement of patients' goals: Perspectives from people living with rheumatoid arthritis enrolled in the ArthritisPower registry.
Arthritis Research and Therapy.
22.
2020
|
|
| 2020
|
Incorporating patient generated health data into pharmacoepidemiological research.
Pharmacoepidemiology and Drug Safety.
2020
|
|
| 2020
|
Severity of Hypertension Mediates the Association of Hyperuricemia With Stroke in the REGARDS Case Cohort Study.
Hypertension.
75:246-256.
2020
|
|
| 2019
|
Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis.
Arthritis Research and Therapy.
21.
2019
|
|
| 2019
|
2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures.
Arthritis Care and Research.
71:1540-1555.
2019
|
|
| 2019
|
International Consortium for Health Outcome Measurement Set of Outcomes That Matter to People Living With Inflammatory Arthritis: Consensus From an International Working Group.
Arthritis Care and Research.
71:1556-1565.
2019
|
|
| 2019
|
PROMIS Fatigue short forms are reliable and valid in adults with rheumatoid arthritis.
Journal of Patient-Reported Outcomes.
3.
2019
|
|
| 2019
|
Screening of Hyperlipidemia Among Patients With Rheumatoid Arthritis in the United States.
Arthritis Care and Research.
71:1593-1599.
2019
|
|
| 2019
|
In response.
ACP journal club.
171:680.
2019
|
|
| 2019
|
Low Persistence Rates in Patients With Rheumatoid Arthritis Treated With Triple Therapy and Adverse Drug Events Associated With Sulfasalazine.
Arthritis Care and Research.
71:1326-1335.
2019
|
|
| 2019
|
The Design and Validation of a New Algorithm to Identify Incident Fractures in Administrative Claims Data.
Journal of Bone and Mineral Research.
34:1798-1807.
2019
|
|
| 2019
|
Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids - Clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole.
Arthritis Research and Therapy.
21.
2019
|
|
| 2019
|
Assessing a novel way to measure three common rehabilitation outcome measures using a custom mobile phone application.
Gait and Posture.
73:246-250.
2019
|
|
| 2019
|
Digital tracking of rheumatoid arthritis longitudinally (digital) using biosensor and patient-reported outcome data: Protocol for a real-world study.
JMIR Research Protocols.
8.
2019
|
|
| 2019
|
Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting.
RMD Open.
5.
2019
|
|
| 2019
|
Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USA.
Rheumatology and Therapy.
6:461-471.
2019
|
|
| 2019
|
Risk for Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids.
Arthritis Care and Research.
71:1249-1254.
2019
|
|
| 2019
|
Timing of Abatacept Before Elective Arthroplasty and Risk of Postoperative Outcomes.
Arthritis Care and Research.
71:1224-1233.
2019
|
|
| 2019
|
Anti-TNF and Physiologic Measures of Metabolic Disease in Rheumatoid Arthritis
2019
|
|
| 2019
|
Tocilizumab and the Risk of Cardiovascular Disease: Direct Comparison Among Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Patients.
Arthritis Care and Research.
71:1004-1018.
2019
|
|
| 2019
|
Assessing a novel way to measure step count while walking using a custom mobile phone application.
PLoS One.
13.
2019
|
|
| 2019
|
Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis.
European Respiratory Journal.
54.
2019
|
|
| 2019
|
The promise and perils of 'Big Data': focus on spondyloarthritis.
Current Opinion in Rheumatology.
31:355-361.
2019
|
|
| 2019
|
Comparison of an interactive voice response system and smartphone application in the identification of gout flares.
Arthritis Research and Therapy.
21.
2019
|
|
| 2019
|
Risk of biologics and glucocorticoids in patients with rheumatoid arthritis undergoing arthroplasty a cohort study.
ACP journal club.
170:825-836.
2019
|
|
| 2019
|
A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis
2019
|
|
| 2019
|
Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis.
Rheumatology.
58:874-883.
2019
|
|
| 2019
|
Digital Interventions to Build a Patient Registry for Rheumatology Research.
Rheumatic Disease Clinics of North America.
45:173-186.
2019
|
|
| 2019
|
Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: A pooled analysis of 11 317 patients across clinical trials.
RMD Open.
5.
2019
|
|
| 2019
|
Opioid use in rheumatoid arthritis: trends, efficacy, safety, and best practices.
Current Opinion in Rheumatology.
31:264-270.
2019
|
|
| 2019
|
The Interface Between Digital Health and Rheumatology.
Rheumatic Disease Clinics of North America.
45:xv-xvi.
2019
|
|
| 2019
|
Tools and Methods for Real-World Evidence Generation: Pragmatic Trials, Electronic Consent, and Data Linkages.
Rheumatic Disease Clinics of North America.
45:275-289.
2019
|
|
| 2019
|
Toward relevant and credible cost-effectiveness analyses for value assessment in the decentralized U.S. health care system.
Journal of managed care & specialty pharmacy.
25:518-521.
2019
|
|
| 2019
|
Data linkages between patient-powered research networks and health plans: A foundation for collaborative research.
Journal of the American Medical Informatics Association.
26:594-602.
2019
|
|
| 2019
|
Improved Quality of Life with Anti-TNF Therapy Compared with Continued Corticosteroid Utilization in Crohn's Disease.
Inflammatory Bowel Diseases.
25:925-936.
2019
|
|
| 2019
|
Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.
Arthritis Research and Therapy.
21.
2019
|
|
| 2019
|
Patient attitudes about non-medical switching to biosimilars: results from an online patient survey in the United States.
Current Medical Research and Opinion.
35:603-609.
2019
|
|
| 2019
|
Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States.
Current Medical Research and Opinion.
35:611-617.
2019
|
|
| 2019
|
Contraception methods used by women with rheumatoid arthritis and psoriatic arthritis.
Clinical Rheumatology.
38:1207-1212.
2019
|
|
| 2019
|
Pregnancy, Periods, and “The Pill”: Exploring the Reproductive Experiences of Women with Inflammatory Arthritis.
ACR Open Rheumatology.
1:125-132.
2019
|
|
| 2019
|
Validity of Privacy-Protecting Analytical Methods That Use only Aggregate-Level Information to Conduct Multivariable-Adjusted Analysis in Distributed Data Networks.
American Journal of Epidemiology.
188:709-723.
2019
|
|
| 2019
|
Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial.
American Journal of Medicine.
132:354-361.
2019
|
|
| 2019
|
Uptake and Clinical Utility of Multibiomarker Disease Activity Testing in the United States.
Journal of Rheumatology.
46:237-244.
2019
|
|
| 2019
|
Determination of the minimally important difference (MID) in multi-biomarker disease activity (MBDA) test scores: impact of diurnal and daily biomarker variation patterns on MBDA scores.
Clinical Rheumatology.
38:437-445.
2019
|
|
| 2019
|
A Novel Method to Combine Assessment of Benefit and Harm: Outcome Measures in Rheumatology 3×3 Methodology Applied to Two Active Comparator Trials.
Arthritis Care and Research.
71:319-322.
2019
|
|
| 2019
|
Response to: 'Can we prescribe TMP/SMX prophylaxis without any concerns equally for all patients with rheumatic disease?' by Suyama and Okada.
Annals of the Rheumatic Diseases.
78.
2019
|
|
| 2019
|
Risk of subsequent fracture after prior fracture among older women.
Osteoporosis International.
30:79-92.
2019
|
|
| 2019
|
Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis.
Annals of the Rheumatic Diseases.
2019
|
|
| 2019
|
Direct-acting antivirals for hepatitis C: Predictors of early discontinuation in the real world.
Journal of managed care & specialty pharmacy.
25:697-704.
2019
|
|
| 2019
|
Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis.
PLoS One.
14.
2019
|
|
| 2019
|
Novel treatment advances and approaches in Rheumatoid arthritis: Personalizing therapy for improved clinical and economic outcomes.
Journal of managed care medicine : JMCM.
22:23-28.
2019
|
|
| 2019
|
Perspectives of Rheumatoid Arthritis Patients on Electronic Communication and Patient-Reported Outcome Data Collection: A Qualitative Study.
Arthritis Care and Research.
71:80-87.
2019
|
|
| 2019
|
Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies.
Current Medical Research and Opinion.
35:1483-1493.
2019
|
|
| 2019
|
Predictors of achieving remission among patients with psoriatic arthritis initiating a tumor necrosis factor inhibitor.
Journal of Rheumatology.
46:475-482.
2019
|
|
| 2019
|
The prevalence and types of discordance between physician perception and objective data from standardized measures of rheumatoid arthritis disease activity in real-world clinical practice in the US.
BMC Rheumatology.
3.
2019
|
|
| 2019
|
Which patient reported outcome domains are important to the rheumatologists while assessing patients with rheumatoid arthritis?.
BMC Rheumatology.
3.
2019
|
|
| 2018
|
Characteristics and Health-care Utilization History of Patients With Bronchiectasis in US Medicare Enrollees With Prescription Drug Plans, 2006 to 2014.
Chest.
154:1311-1320.
2018
|
|
| 2018
|
Diet and exercise changes following bone densitometry in the Patient Activation After DXA Result Notification (PAADRN) study.
Archives of Osteoporosis.
13.
2018
|
|
| 2018
|
Importance of Recent Fracture as Predictor of Imminent Fracture Risk.
Current Osteoporosis Reports.
16:738-745.
2018
|
|
| 2018
|
Correction to: Hip fracture trends in the United States, 2002 to 2015 (Osteoporosis International, (2018), 29, 3, (717-722), 10.1007/s00198-017-4345-0).
Osteoporosis International.
29:2583.
2018
|
|
| 2018
|
Is Rheumatoid Arthritis a Cardiovascular Risk-Equivalent to Diabetes Mellitus?.
Arthritis Care and Research.
70:1694-1699.
2018
|
|
| 2018
|
Evaluation of a Methodologic Approach to Define an Inception Cohort of Rheumatoid Arthritis Patients Using Administrative Data.
Arthritis Care and Research.
70:1541-1545.
2018
|
|
| 2018
|
Glucocorticoid Exposure and Fracture Risk in a Cohort of US Patients With Selected Conditions.
Journal of Bone and Mineral Research.
33:1881-1888.
2018
|
|
| 2018
|
Patient Governance in a Patient-Powered Research Network for Adult Rheumatologic Conditions.
Medical Care.
56:S16-S21.
2018
|
|
| 2018
|
Serious Infections in Rheumatoid Arthritis Offspring Exposed to Tumor Necrosis Factor Inhibitors: A Cohort Study.
Arthritis and Rheumatology.
70:1565-1571.
2018
|
|
| 2018
|
A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences.
Advances in Therapy.
35:1333-1355.
2018
|
|
| 2018
|
Combining online and in-person methods to evaluate the content validity of PROMIS fatigue short forms in rheumatoid arthritis.
Quality of Life Research.
27:2443-2451.
2018
|
|
| 2018
|
Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study.
Clinical Rheumatology.
37:2331-2340.
2018
|
|
| 2018
|
Opioids vs nonopioids for chronic back, hip, or knee pain.
Journal of the American Medical Association.
320:508.
2018
|
|
| 2018
|
An Observational Study of Cardiovascular Risks Associated with Rheumatoid Arthritis Therapies: A Comparison of Two Analytical Approaches.
The Permanente Journal.
22.
2018
|
|
| 2018
|
Development of algorithms for identifying fatal cardiovascular disease in Medicare claims.
Pharmacoepidemiology and Drug Safety.
27:740-750.
2018
|
|
| 2018
|
Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors.
Annals of the Rheumatic Diseases.
77:1012-1016.
2018
|
|
| 2018
|
Gastrointestinal Perforations with Biologics in Patients with Rheumatoid Arthritis: Implications for Clinicians.
Drug Safety.
41:545-553.
2018
|
|
| 2018
|
Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept
2018
|
|
| 2018
|
Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis.
Rheumatology and Therapy.
5:283-291.
2018
|
|
| 2018
|
Factors associated with physicians' prescriptions for rheumatoid arthritis drugs not filled by patients.
Arthritis Research and Therapy.
20.
2018
|
|
| 2018
|
Evaluation of a Multimodal, Direct-to-Patient Educational Intervention Targeting Barriers to Osteoporosis Care: A Randomized Clinical Trial.
Journal of Bone and Mineral Research.
33:763-772.
2018
|
|
| 2018
|
Impact of Sustained Remission on the Risk of Serious Infection in Patients With Rheumatoid Arthritis.
Arthritis Care and Research.
70:679-684.
2018
|
|
| 2018
|
Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis.
PLoS One.
13.
2018
|
|
| 2018
|
Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids.
Annals of the Rheumatic Diseases.
77:644-649.
2018
|
|
| 2018
|
Reply.
Arthritis and Rheumatology.
70:795-796.
2018
|
|
| 2018
|
Defining and characterizing sustained remission in patients with rheumatoid arthritis.
Clinical Rheumatology.
37:885-893.
2018
|
|
| 2018
|
Use of Scribes for Documentation Assistance in Rheumatology and Endocrinology Clinics: Impact on Clinic Workflow and Patient and Physician Satisfaction
2018
|
|
| 2018
|
Effectiveness and safety of tofacitinib in rheumatoid arthritis: A cohort study.
Arthritis Research and Therapy.
20.
2018
|
|
| 2018
|
Biomarker-related risk for myocardial infarction and serious infections in patients with rheumatoid arthritis: A population-based study.
Annals of the Rheumatic Diseases.
77:386-392.
2018
|
|
| 2018
|
Hip fracture trends in the United States, 2002 to 2015.
Osteoporosis International.
29:717-722.
2018
|
|
| 2018
|
Increased mortality rates with prolonged corticosteroid therapy when compared with antitumor necrosis factor-α-directed therapy for inflammatory bowel disease.
American Journal of Gastroenterology.
113:405-417.
2018
|
|
| 2018
|
Advancing the Science and Practice of Medication Adherence.
Journal of General Internal Medicine.
33:216-222.
2018
|
|
| 2018
|
Influence of obesity, age, and comorbidities on the multi-biomarker disease activity test in rheumatoid arthritis.
Seminars in Arthritis and Rheumatism.
47:472-477.
2018
|
|
| 2018
|
Just the FRAX: Management of Glucocorticoid-Induced Osteoporosis.
Gastroenterology.
154:748-750.
2018
|
|
| 2018
|
Reply.
Arthritis and Rheumatology.
70:320.
2018
|
|
| 2018
|
Incidence and prevalence of axial spondyloarthritis: Methodologic challenges and gaps in the literature.
Clinical and Experimental Rheumatology.
36:263-274.
2018
|
|
| 2018
|
Lipid management among individuals with inflammatory arthritis in the national REasons for geographic and racial differences in stroke (REGARDS) cohort.
Journal of International Medical Research.
46:62-69.
2018
|
|
| 2018
|
Routine use of quantitative disease activity measurements among us rheumatologists: Implications for treat-to-target management strategies in rheumatoid arthritis.
Journal of Rheumatology.
45:40-44.
2018
|
|
| 2017
|
Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment.
Arthritis Research and Therapy.
19.
2017
|
|
| 2017
|
Studies with herpes zoster vaccines in immune compromised patients.
Expert Review of Vaccines.
16:1217-1230.
2017
|
|
| 2017
|
Critical outcomes in longitudinal observational studies and registries in patients with rheumatoid arthritis: An OMERACT special interest group report.
Journal of Rheumatology.
44:1894-1898.
2017
|
|
| 2017
|
Herpes Zoster as a Risk Factor for Incident Giant Cell Arteritis.
Arthritis and Rheumatology.
69:2351-2358.
2017
|
|
| 2017
|
Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip and Knee Arthroplasty.
Arthritis Care and Research.
69:1845-1854.
2017
|
|
| 2017
|
Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis: Results From an NTM Info & Research Patient Survey and the Bronchiectasis and NTM Research Registry.
Chest.
152:1120-1127.
2017
|
|
| 2017
|
Serious Infections in Childhood-Onset Systemic Lupus Erythematosus: Using Administrative Claims Data to Investigate Disease Outcomes.
Arthritis Care and Research.
69:1617-1619.
2017
|
|
| 2017
|
Is gout a risk equivalent to diabetes for stroke and myocardial infarction? A retrospective claims database study.
Arthritis Research and Therapy.
19.
2017
|
|
| 2017
|
Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.
Arthritis and Rheumatology.
69:1960-1968.
2017
|
|
| 2017
|
Risk of Hypersensitivity to Biologic Agents Among Medicare Patients With Rheumatoid Arthritis.
Arthritis Care and Research.
69:1526-1534.
2017
|
|
| 2017
|
The cost of a patient activation intervention for achieving successful outcomes: results from the PAADRN randomized controlled trial.
Osteoporosis International.
28:3061-3066.
2017
|
|
| 2017
|
The effects of a patient activation intervention on smoking and excessive drinking cessations: results from the PAADRN randomized controlled trial.
Osteoporosis International.
28:3055-3060.
2017
|
|
| 2017
|
A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: Post-hoc results from the certolizumab pegol phase 4 PREDICT trial.
Arthritis Research and Therapy.
19.
2017
|
|
| 2017
|
Changing Trends in Opioid Use Among Patients With Rheumatoid Arthritis in the United States.
Arthritis and Rheumatology.
69:1733-1740.
2017
|
|
| 2017
|
Stakeholders' views on data sharing in multicenter studies.
Journal of Comparative Effectiveness Research.
6:537-547.
2017
|
|
| 2017
|
Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study.
Osteoporosis International.
28:2495-2503.
2017
|
|
| 2017
|
Erratum to: Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study (Osteoporosis International, (2017), 28, 8, (2495-2503), 10.1007/s00198-017-4073-5).
Osteoporosis International.
28:2505.
2017
|
|
| 2017
|
Systematic Literature Review and Meta-analysis of Tumor Necrosis Factor–Alpha Experienced Rheumatoid Arthritis
2017
|
|
| 2017
|
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: Integrated analysis of data from the global clinical trials.
Annals of the Rheumatic Diseases.
76:1253-1262.
2017
|
|
| 2017
|
Longterm effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseases.
Journal of Rheumatology.
44:1083-1087.
2017
|
|
| 2017
|
Knee Pain and Structural Damage as Risk Factors for Incident Widespread Pain: Data From the Multicenter Osteoarthritis Study.
Arthritis Care and Research.
69:826-832.
2017
|
|
| 2017
|
Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: A retrospective claims analysis.
Arthritis Research and Therapy.
19.
2017
|
|
| 2017
|
Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis
2017
|
|
| 2017
|
Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis.
Clinical and Experimental Rheumatology.
35:0390-0400.
2017
|
|
| 2017
|
Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis c virus infection.
Journal of Rheumatology.
44:565-570.
2017
|
|
| 2017
|
Improving medical record retrieval for validation studies in Medicare data.
Pharmacoepidemiology and Drug Safety.
26:393-401.
2017
|
|
| 2017
|
Reanalysis of the Multi-Biomarker Disease Activity Score for Assessing Disease Activity in the Abatacept Versus Adalimumab Comparison in Biologic-Naive Rheumatoid Arthritis Subjects with Background Methotrexate Study: Comment on the Article by Fleischmann et al.
Arthritis and Rheumatology.
69:863-865.
2017
|
|
| 2017
|
Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes.
BMC Cardiovascular Disorders.
17.
2017
|
|
| 2017
|
Social media for arthritis-related comparative effectiveness and safety research and the impact of direct-to-consumer advertising.
Arthritis Research and Therapy.
19.
2017
|
|
| 2017
|
Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis.
Arthritis Care and Research.
69:313-322.
2017
|
|
| 2017
|
The clinical status and economic savings associated with remission among patients with rheumatoid arthritis: leveraging linked registry and claims data for synergistic insights.
Pharmacoepidemiology and Drug Safety.
26:310-319.
2017
|
|
| 2017
|
Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib.
Clinical Rheumatology.
36:683-688.
2017
|
|
| 2017
|
Herpes Zoster and the Risk of Stroke in Patients With Autoimmune Diseases.
Arthritis and Rheumatology.
69:439-446.
2017
|
|
| 2017
|
Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programme.
Clinical and Experimental Rheumatology.
35:614-622.
2017
|
|
| 2017
|
Association of 3 different antihypertensive medications with hip and pelvic fracture risk in older adults secondary analysis of a randomized clinical trial.
JAMA Internal Medicine.
177:67-76.
2017
|
|
| 2017
|
Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis..
Clinical and Experimental Rheumatology.
35:390-400.
2017
|
|
| 2017
|
Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial.
Arthritis and Rheumatology.
69:46-57.
2017
|
|
| 2016
|
A multi-modal intervention for Activating Patients at Risk for Osteoporosis (APROPOS): Rationale, design, and uptake of online study intervention material.
Contemporary Clinical Trials Communications.
4:14-24.
2016
|
|
| 2016
|
Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study
2016
|
|
| 2016
|
Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication.
ClinicoEconomics and Outcomes Research.
8:707-715.
2016
|
|
| 2016
|
Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry.
Arthritis Research and Therapy.
18.
2016
|
|
| 2016
|
Cost-Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis.
Arthritis Care and Research.
68:1751-1757.
2016
|
|
| 2016
|
Population Variations in Rheumatoid Arthritis Treatment and Outcomes, Northern California, 1998-2009.
The Permanente Journal.
20:4-12.
2016
|
|
| 2016
|
Usability and workflow evaluation of “RhEumAtic disease activity” (READY): A mobile application for rheumatology patients and providers.
Applied Clinical Informatics.
7:1007-1024.
2016
|
|
| 2016
|
Adherence and persistence with methotrexate in rheumatoid arthritis: A systematic review.
Journal of Rheumatology.
43:1997-2009.
2016
|
|
| 2016
|
Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.
Arthritis and Rheumatology.
68:2612-2617.
2016
|
|
| 2016
|
Comparison of certolizumab pegol versus adalimumab: Results of efficacy and tolerability at 2 years of an investigator-blinded, direct comparative superiority study.
Revue du Rhumatisme.
83:A125-A126.
2016
|
|
| 2016
|
Erratum: Corrigendum to “Initial Experience With Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination With Conventional Synthetic DMARDs in 2 US Health Care Claims Databases” (Clinical Therapeutics (2016) 38(6) (1451–1463)(S0149291816301849)(10.1016/j.clinthera.2016.03.038))
2016
|
|
| 2016
|
Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis.
Osteoporosis International.
27:3239-3249.
2016
|
|
| 2016
|
Association of anti-peptidyl arginine deiminase antibodies with radiographic severity of rheumatoid arthritis in African Americans.
Arthritis Research and Therapy.
18.
2016
|
|
| 2016
|
Association Between Breast Cancer Recurrence and Immunosuppression in Rheumatoid Arthritis and Inflammatory Bowel Disease: A Cohort Study.
Arthritis and Rheumatology.
68:2403-2411.
2016
|
|
| 2016
|
Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis.
Annals of the Rheumatic Diseases.
75:1813-1818.
2016
|
|
| 2016
|
Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis.
Annals of the Rheumatic Diseases.
75:1757-1762.
2016
|
|
| 2016
|
Linkage of a Population-Based Cohort with Primary Data Collection to Medicare Claims.
American Journal of Epidemiology.
184:532-544.
2016
|
|
| 2016
|
Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis.
Annals of the Rheumatic Diseases.
75:1843-1847.
2016
|
|
| 2016
|
Patient's experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis.
BMC Musculoskeletal Disorders.
17.
2016
|
|
| 2016
|
The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis.
Arthritis Research and Therapy.
18.
2016
|
|
| 2016
|
Analysis of health care claims during the peri-transfer stage of transition from pediatric to adult care among juvenile idiopathic arthritis patients
2016
|
|
| 2016
|
Diagnostic Prevalence of Ankylosing Spondylitis Using Computerized Health Care Data, 1996 to 2009: Underrecognition in a US Health Care Setting.
The Permanente Journal.
20:4-10.
2016
|
|
| 2016
|
Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein–Enriched Serum in Rheumatoid Arthritis.
Arthritis and Rheumatology.
68:2099-2105.
2016
|
|
| 2016
|
Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) Study.
Contemporary Clinical Trials.
50:106-115.
2016
|
|
| 2016
|
Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination.
Arthritis and Rheumatology.
68:2328-2337.
2016
|
|
| 2016
|
Effects of a DXA result letter on satisfaction, quality of life, and osteoporosis knowledge: A randomized controlled trial.
BMC Musculoskeletal Disorders.
17.
2016
|
|
| 2016
|
A pragmatic randomized trial comparing tablet computer informed consent to traditional paper-based methods for an osteoporosis study.
Contemporary Clinical Trials Communications.
3:32-38.
2016
|
|
| 2016
|
Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis.
Advances in Therapy.
33:1347-1359.
2016
|
|
| 2016
|
What Proportion of Incident Radiographic Vertebral Fractures in Older Men Is Clinically Diagnosed and Vice Versa: A Prospective Study.
Journal of Bone and Mineral Research.
31:1500-1503.
2016
|
|
| 2016
|
Survival rates of cancer patients with and without rheumatic disease: A retrospective cohort analysis.
BMC Cancer.
16.
2016
|
|
| 2016
|
Agreement between Medicare pharmacy claims, self-report, and medication inventory for assessing lipid-lowering medication use.
Pharmacoepidemiology and Drug Safety.
25:827-835.
2016
|
|
| 2016
|
Frequency of Axial Spondyloarthritis Diagnosis Among Patients Seen by US Rheumatologists for Evaluation of Chronic Back Pain.
Arthritis and Rheumatology.
68:1669-1676.
2016
|
|
| 2016
|
Agreement between rheumatologist and patient-reported adherence to methotrexate in a US rheumatoid arthritis registry.
Journal of Rheumatology.
43:1027-1029.
2016
|
|
| 2016
|
Dosing of Intravenous Tocilizumab in a Real-World Setting of Rheumatoid Arthritis: Analyses from the Corrona Registry.
Rheumatology and Therapy.
3:103-115.
2016
|
|
| 2016
|
Initial Experience with Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination with Conventional Synthetic DMARDs in 2 US Health Care Claims Databases
2016
|
|
| 2016
|
Reenergizing Research While Improving Patient Care.
Provider (Washington, D.C.).
42.
2016
|
|
| 2016
|
Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept.
BMC Musculoskeletal Disorders.
17.
2016
|
|
| 2016
|
Tofacitinib, an oral Janus kinase inhibitor: Analysis of malignancies across the rheumatoid arthritis clinical development programme.
Annals of the Rheumatic Diseases.
75:831-841.
2016
|
|
| 2016
|
Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations.
Arthritis Research and Therapy.
18.
2016
|
|
| 2016
|
Association of Triple Therapy with Improvement in Cholesterol Profiles over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial.
Arthritis and Rheumatology.
68:577-586.
2016
|
|
| 2016
|
Comparative effectiveness of etanercept and adalimumab in patient reported outcomes and injection-related tolerability.
PLoS One.
11.
2016
|
|
| 2016
|
Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: Data from the National Veterans Health Administration.
Annals of the Rheumatic Diseases.
75:341-347.
2016
|
|
| 2016
|
Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer.
JAMA Dermatology.
152:164-172.
2016
|
|
| 2016
|
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.
Arthritis and Rheumatology.
68:1-26.
2016
|
|
| 2016
|
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.
Arthritis Care and Research.
68:1-26.
2016
|
|
| 2016
|
Association of reduced eGFR and albuminuria with serious fall injuries among older adults.
Clinical Journal of the American Society of Nephrology.
11:1236-1243.
2016
|
|
| 2016
|
Comparative Risk of Hospitalized Infection Associated with Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
Arthritis and Rheumatology.
68:56-66.
2016
|
|
| 2016
|
Risk of Cardiovascular Outcomes among Psoriasis Patients Treated with Biologics and Other Systemic Agents.
2016
|
|
| 2016
|
Risk of Subsequent Infection among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.
Arthritis and Rheumatology.
68:67-76.
2016
|
|
| 2015
|
A randomized trial comparing disease activity measures for the assessment and prediction of response in rheumatoid arthritis patients initiating certolizumab pegol.
Arthritis and Rheumatology.
67:3104-3112.
2015
|
|
| 2015
|
Herpes Zoster Reactivation in Patients with Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs.
Arthritis Care and Research.
67:1671-1678.
2015
|
|
| 2015
|
The Risk for Cardiovascular Events Associated with Hyperlipdemia among Patients with and Without Rheumatoid Arthritis..
Journal of Arthritis.
4.
2015
|
|
| 2015
|
The comparative effectiveness of biologics among older adults and disabled rheumatoid arthritis patients in the Medicare population.
British Journal of Clinical Pharmacology.
80:1447-1457.
2015
|
|
| 2015
|
Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor aα agents, a retrospective cohort study.
Arthritis Research and Therapy.
17.
2015
|
|
| 2015
|
Bone mineral density as a predictor of subsequent wrist fractures: Findings from the women's health initiative study.
Journal of Clinical Endocrinology and Metabolism.
100:4315-4324.
2015
|
|
| 2015
|
Effectiveness and costs of biologics in veterans with rheumatoid arthritis.
The American journal of pharmacy benefits.
7:280-289.
2015
|
|
| 2015
|
Methotrexate Adherence Questionnaire: a New Tool to Assess Adherence in Patients Treated with Methotrexate..
Value in Health.
18:A714-A715.
2015
|
|
| 2015
|
Optimal Use of Available Claims to Identify a Medicare Population Free of Coronary Heart Disease.
American Journal of Epidemiology.
182:808-819.
2015
|
|
| 2015
|
Wrist Fracture and Risk of Subsequent Fracture: Findings from the Women's Health Initiative Study.
Journal of Bone and Mineral Research.
30:2086-2095.
2015
|
|
| 2015
|
Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients.
Arthritis Care and Research.
67:1345-1353.
2015
|
|
| 2015
|
Analysis of osteoporosis treatment patterns with bisphosphonates and outcomes among postmenopausal veterans.
Bone.
78:174-185.
2015
|
|
| 2015
|
Heterogeneous disease trajectories explain variable radiographic, function and quality of life outcomes in the Canadian Early Arthritis Cohort (CATCH).
PLoS One.
10.
2015
|
|
| 2015
|
Mortality associated with medical therapy versus elective colectomy in ulcerative colitis a cohort study.
ACP journal club.
163:262-270.
2015
|
|
| 2015
|
An internet-based controlled trial aimed to improve osteoporosis prevention among chronic glucocorticoid users.
Journal of Rheumatology.
42:1478-1483.
2015
|
|
| 2015
|
Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: A consortium of rheumatology researchers of North America registry study.
Arthritis and Rheumatology.
67:1995-2003.
2015
|
|
| 2015
|
The validity of claims-based algorithms to identify serious hypersensitivity reactions and osteonecrosis of the jaw.
PLoS One.
10.
2015
|
|
| 2015
|
Comprehensive appraisal of magnetic resonance imaging findings in sustained rheumatoid arthritis remission: A substudy.
Arthritis Care and Research.
67:929-939.
2015
|
|
| 2015
|
Effectiveness and safety of immunomodulators with anti-tumor necrosis factor therapy in crohn's disease.
Clinical Gastroenterology and Hepatology.
13:1293-1301.e5.
2015
|
|
| 2015
|
Reply.
Arthritis Care and Research.
67:1041-1042.
2015
|
|
| 2015
|
Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: Persistent benefits. Data from the Corrona registry.
Annals of the Rheumatic Diseases.
74:1150-1155.
2015
|
|
| 2015
|
Disease activity in rheumatoid arthritis and the risk of cardiovascular events.
Arthritis and Rheumatology.
67:1449-1455.
2015
|
|
| 2015
|
Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.
Annals of the Rheumatic Diseases.
74:1065-1071.
2015
|
|
| 2015
|
Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab.
Arthritis and Rheumatology.
67:1456-1464.
2015
|
|
| 2015
|
Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: A retrospective cohort study.
Arthritis Research and Therapy.
17.
2015
|
|
| 2015
|
Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients.
Arthritis Care and Research.
67:624-632.
2015
|
|
| 2015
|
Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy.
Arthritis Care and Research.
67:731-736.
2015
|
|
| 2015
|
DXA utilization between 2006 and 2012 in commercially insured younger postmenopausal women.
Journal of Clinical Densitometry.
18:145-149.
2015
|
|
| 2015
|
Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system.
Journal of Rheumatology.
42:504-512.
2015
|
|
| 2015
|
Proceedings from the American College of Rheumatology Reproductive Health Summit: The management of fertility, pregnancy, and lactation in women with autoimmune and systemic inflammatory diseases.
Arthritis Care and Research.
67:313-325.
2015
|
|
| 2015
|
An evaluation of clinical risk factors for estimating fracture risk in postmenopausal osteoporosis using an electronic medical record database.
Osteoporosis International.
26:581-587.
2015
|
|
| 2015
|
The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor.
Annals of the Rheumatic Diseases.
74:430-436.
2015
|
|
| 2015
|
Validation study of medicare claims to identify older US adults with CKD using the reasons for geographic and racial differences in stroke (REGARDS) study.
American Journal of Kidney Diseases.
65:249-258.
2015
|
|
| 2015
|
Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population.
Journal of managed care & specialty pharmacy.
21:318-328.
2015
|
|
| 2015
|
Fractures and mortality in relation to different osteoporosis treatments.
Clinical and Experimental Rheumatology.
33:302-309.
2015
|
|
| 2015
|
International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study.
Osteoporosis International.
26:419-420.
2015
|
|
| 2015
|
Tocilizumab in rheumatoid arthritis: A case study of safety evaluations of a large postmarketing data set from multiple data sources.
Seminars in Arthritis and Rheumatism.
44:381-388.
2015
|
|
| 2014
|
Linkage of a de-identified united states rheumatoid arthritis registry with administrative data to facilitate comparative effectiveness research.
Arthritis Care and Research.
66:1790-1798.
2014
|
|
| 2014
|
The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis.
Postgraduate Medical Journal.
90:722-729.
2014
|
|
| 2014
|
Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: Results of the SAfety assessment of biologic ThERapy (SABER) study.
Annals of the Rheumatic Diseases.
73:1942-1948.
2014
|
|
| 2014
|
The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine.
Journal of Bone and Mineral Research.
29:2520-2526.
2014
|
|
| 2014
|
Use of Oral and Subcutaneous Methotrexate in Rheumatoid Arthritis Patients in the United States.
Arthritis Care and Research.
66:1604-1611.
2014
|
|
| 2014
|
Bisphosphonates and hip and nontraumatic subtrochanteric femoral fractures in the veterans health administration
2014
|
|
| 2014
|
Initiation of TNF inhibitor therapy and change in physiologic measures in psoriasis.
Journal of the European Academy of Dermatology and Venereology.
28:1380-1387.
2014
|
|
| 2014
|
Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis.
Journal of Rheumatology.
41:1935-1943.
2014
|
|
| 2014
|
Recent trends in medication usage for the treatment of juvenile idiopathic arthritis and the influence of tumor necrosis factor inhibitors.
Journal of Rheumatology.
41:2078-2084.
2014
|
|
| 2014
|
Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs.
Arthritis Research and Therapy.
16.
2014
|
|
| 2014
|
Estimating effectiveness and cost of biologics for rheumatoid arthritis: Application of a validated algorithm to commercial insurance claims
2014
|
|
| 2014
|
Validity of claims-based stroke algorithms in contemporary medicare data: Reasons for geographic and racial differences in stroke (REGARDS) study linked with medicare claims.
Circulation: Cardiovascular Quality and Outcomes.
7:611-619.
2014
|
|
| 2014
|
Claims-based algorithms for identifying Medicare beneficiaries at high estimated risk for coronary heart disease events: A cross-sectional study.
BMC Health Services Research.
14.
2014
|
|
| 2014
|
Design characteristics of the CORRONA CERTAIN study: A comparative effectiveness study of biologic agents for rheumatoid arthritis patients.
BMC Musculoskeletal Disorders.
15.
2014
|
|
| 2014
|
Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiaries.
BMC Musculoskeletal Disorders.
15.
2014
|
|
| 2014
|
Death, debility, and destitution following hip fracture
2014
|
|
| 2014
|
Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs.
Seminars in Arthritis and Rheumatism.
43:489-497.
2014
|
|
| 2014
|
Continued benefit of tocilizumab plus disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis and inadequate clinical responses by week 8 of treatment.
Journal of Rheumatology.
41:216-226.
2014
|
|
| 2014
|
Genetic variants associated with methotrexate efficacy and toxicity in early rheumatoid arthritis: Results from the treatment of early aggressive rheumatoid arthritis trial
2014
|
|
| 2014
|
High plasma levels of vitamin C and E are associated with incident radiographic knee osteoarthritis.
Osteoarthritis and Cartilage.
22:190-196.
2014
|
|
| 2014
|
Use of health plan combined with registry data to predict clinical trial recruitment.
Clinical Trials.
11:96-101.
2014
|
|
| 2014
|
A case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumab.
Annals of the Rheumatic Diseases.
73:1429-1430.
2014
|
|
| 2014
|
Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American society for bone and mineral research.
Journal of Bone and Mineral Research.
29:1-23.
2014
|
|
| 2014
|
Comparative effectiveness of infliximab and adalimumab for crohn's disease.
Clinical Gastroenterology and Hepatology.
12:811-817.e3.
2014
|
|
| 2014
|
Considerations in using registry and health plan data for studying pregnancy in rheumatic diseases.
Current Opinion in Rheumatology.
26:315-320.
2014
|
|
| 2014
|
Effect of self-referral on bone mineral density testing and osteoporosis treatment.
Medical Care.
52:743-750.
2014
|
|
| 2014
|
Gene-body mass index interactions are associated with methotrexate toxicity in rheumatoid arthritis.
Annals of the Rheumatic Diseases.
73:785-786.
2014
|
|
| 2014
|
Reply.
Arthritis Care and Research.
66:1271-1272.
2014
|
|
| 2014
|
Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis.
Arthritis Care and Research.
66:990-997.
2014
|
|
| 2014
|
Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-Label, longterm extension studies.
Journal of Rheumatology.
41:837-852.
2014
|
|
| 2014
|
The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis.
Annals of the Rheumatic Diseases.
73:1301-1308.
2014
|
|
| 2014
|
Trends in the utilization and outcomes of medicare patients hospitalized for hip fracture, 2000-2008.
Journal of Aging and Health.
26:360-379.
2014
|
|
| 2014
|
Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritis
2014
|
|
| 2014
|
Use of pharmacologic agents for the primary prevention of osteoporosis among older women with low bone mass.
Osteoporosis International.
25:317-324.
2014
|
|
| 2014
|
Vaccinations for rheumatoid arthritis.
Current Rheumatology Reports.
16.
2014
|
|
| 2013
|
Commentary: Measuring quality of care in osteoporosis.
Current Osteoporosis Reports.
11:338-340.
2013
|
|
| 2013
|
Commentary: The five ws of a fracture liaison service: Why, who, what, where, and how? in osteoporosis, we reap what we sow.
Current Osteoporosis Reports.
11:365-368.
2013
|
|
| 2013
|
Epidemiologic research of invasive fungal infections using large healthcare databases.
Current Fungal Infection Reports.
7:320-325.
2013
|
|
| 2013
|
Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist.
Annals of the Rheumatic Diseases.
72:1813-1818.
2013
|
|
| 2013
|
Identifying newly approved medications in Medicare claims data: A case study using tocilizumab.
Pharmacoepidemiology and Drug Safety.
22:1214-1221.
2013
|
|
| 2013
|
Tumor necrosis factor, tuberculosis, testing, and treatment: Teeing up the questions.
Arthritis Care and Research.
65:1719-1721.
2013
|
|
| 2013
|
Tumor necrosis factor, tuberculosis, testing, and treatment: teeing up the questions..
Arthritis Care and Research.
65:1719-1721.
2013
|
|
| 2013
|
Using registries to identify adverse events in rheumatic diseases.
Pediatrics.
132.
2013
|
|
| 2013
|
Challenges in defining quality of care for glucocorticoid-induced osteoporosis: Defending good against perfect.
Journal of Rheumatology.
40:1640-1642.
2013
|
|
| 2013
|
Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia® (denosumab) for the treatment of postmenopausal osteoporosis.
Pharmacoepidemiology and Drug Safety.
22:1107-1114.
2013
|
|
| 2013
|
Multimodal intervention to improve osteoporosis care in home health settings: Results from a cluster randomized trial.
Osteoporosis International.
24:2555-2560.
2013
|
|
| 2013
|
Patient perspectives on achieving treat-to-target goals: A critical examination of patient-reported outcomes.
Arthritis Care and Research.
65:1707-1712.
2013
|
|
| 2013
|
Predictors and persistence of new-onset clinical remission in rheumatoid arthritis patients.
Seminars in Arthritis and Rheumatism.
43:137-143.
2013
|
|
| 2013
|
Reply.
American Journal of Ophthalmology.
156:408.
2013
|
|
| 2013
|
Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: Results from a two-year randomized, double-blind trial.
Arthritis and Rheumatism.
65:1985-1994.
2013
|
|
| 2013
|
Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009.
Pharmacoepidemiology and Drug Safety.
22:842-849.
2013
|
|
| 2013
|
Incidence and prevalence of juvenile idiopathic arthritis among children in a managed care population, 1996-2009.
Journal of Rheumatology.
40:1218-1225.
2013
|
|
| 2013
|
Initiation of tumor necrosis factor α antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseases.
Arthritis Care and Research.
65:1085-1094.
2013
|
|
| 2013
|
Osteoporosis medication adherence: Physician perceptions vs. patients' utilization.
Bone.
55:1-6.
2013
|
|
| 2013
|
Early effects of tocilizumab in the treatment of moderate to severe active rheumatoid arthritis: A one-week sub-study of a randomised controlled trial (Rapid Onset and Systemic Efficacy [ROSE] Study).
Clinical and Experimental Rheumatology.
31:358-364.
2013
|
|
| 2013
|
Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: Results from the treatment of early rheumatoid arthritis trial.
Arthritis and Rheumatism.
65:1430-1438.
2013
|
|
| 2013
|
Brief report: Incidence of selected opportunistic infections among children with juvenile idiopathic arthritis.
Arthritis and Rheumatism.
65:1384-1389.
2013
|
|
| 2013
|
Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA: Results from the TEAR trial.
Journal of Rheumatology.
40:572-578.
2013
|
|
| 2013
|
New methods for determining comparative effectiveness in rheumatoid arthritis.
Current Opinion in Rheumatology.
25:325-333.
2013
|
|
| 2013
|
Newest clinical trial results with antitumor necrosis factor and nonantitumor necrosis factor biologics for rheumatoid arthritis.
Current Opinion in Rheumatology.
25:384-390.
2013
|
|
| 2013
|
Development of a Multi-Biomarker Disease Activity Test for Rheumatoid Arthritis.
PLoS One.
8.
2013
|
|
| 2013
|
A close examination of healthcare expenditures related to fractures.
Journal of Bone and Mineral Research.
28:816-820.
2013
|
|
| 2013
|
Association between anti-TNF-α therapy and interstitial lung disease.
Pharmacoepidemiology and Drug Safety.
22:394-402.
2013
|
|
| 2013
|
Performance of FRAX in a cohort of community-dwelling, ambulatory older men: The Osteoporotic Fractures in Men (MrOS) study.
Osteoporosis International.
24:1185-1193.
2013
|
|
| 2013
|
Further evaluation of a claims-based algorithm to determine the effectiveness of biologics for rheumatoid arthritis using commercial claims data.
Arthritis Research and Therapy.
15.
2013
|
|
| 2013
|
Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.
Journal of the American Medical Association.
309:887-895.
2013
|
|
| 2013
|
Magnitude and consequences of misclassification of incident hip fractures in large cohort studies: The Study of Osteoporotic Fractures and Medicare claims data.
Osteoporosis International.
24:801-810.
2013
|
|
| 2013
|
Comparative effectiveness of nonbiologic versus biologic disease-modifying antirheumatic drugs for rheumatoid arthritis.
Journal of Rheumatology.
40:127-136.
2013
|
|
| 2013
|
Physicians' explanations for apparent gaps in the quality of rheumatology care: Results from the US Medicare Physician Quality Reporting System.
Arthritis Care and Research.
65:235-243.
2013
|
|
| 2013
|
Cardiovascular risk in rheumatoid arthritis: Comparing tnf-α blockade with nonbiologic DMARDs.
American Journal of Medicine.
126:730.e9-730.e17.
2013
|
|
| 2013
|
Generic alendronate use among medicare beneficiaries: Are part d data complete?.
Pharmacoepidemiology and Drug Safety.
22:55-63.
2013
|
|
| 2013
|
Initiation of anti-TNF therapy and the risk of optic neuritis: From the safety assessment of biologic ThERapy (SABER) study.
American Journal of Ophthalmology.
155:183-189.e1.
2013
|
|
| 2013
|
Low hemoglobin levels and recurrent falls in U.S. Men and Women: Prospective findings from the REasons for Geographic and racial differences in stroke (REGARDS) cohort.
American Journal of the Medical Sciences.
345:446-454.
2013
|
|
| 2013
|
Mycobacterial diseases and antitumour necrosis factor therapy in USA.
Annals of the Rheumatic Diseases.
72:37-42.
2013
|
|
| 2013
|
Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis
2013
|
|
| 2013
|
The PAADRN Study: A design for a randomized controlled practical clinical trial to improve bone health.
Contemporary Clinical Trials.
34:90-100.
2013
|
|
| 2013
|
Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare program.
Arthritis Care and Research.
65:1743-1751.
2013
|
|
| 2013
|
Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases.
Arthritis and Rheumatism.
65:48-58.
2013
|
|
| 2013
|
Using tablet computers compared to interactive voice response to improve subject recruitment in osteoporosis pragmatic clinical trials: Feasibility, satisfaction, and sample size.
Patient Preference and Adherence.
7:517-523.
2013
|
|
| 2012
|
A randomized trial of a mailed intervention and self-scheduling to improve osteoporosis screening in postmenopausal women.
Journal of Bone and Mineral Research.
27:2603-2610.
2012
|
|
| 2012
|
Association between anti-TNF-α therapy and all-cause mortality.
Pharmacoepidemiology and Drug Safety.
21:1311-1320.
2012
|
|
| 2012
|
Does medication adherence itself confer fracture protection? An investigation of the healthy adherer effect in observational data.
Arthritis Care and Research.
64:1855-1863.
2012
|
|
| 2012
|
Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis.
Arthritis Care and Research.
64:1819-1828.
2012
|
|
| 2012
|
Serum cotinine as a biomarker of tobacco exposure and the association with treatment response in early rheumatoid arthritis.
Arthritis Care and Research.
64:1804-1810.
2012
|
|
| 2012
|
Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity.
Arthritis Care and Research.
64:1794-1803.
2012
|
|
| 2012
|
Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United States.
Contemporary Clinical Trials.
33:1211-1216.
2012
|
|
| 2012
|
Recent trends in hip fracture rates by race/ethnicity among older US adults.
Journal of Bone and Mineral Research.
27:2325-2332.
2012
|
|
| 2012
|
Postherpetic neuralgia after herpes zoster vaccination - Reply.
Journal of the American Medical Association.
308:1427-1428.
2012
|
|
| 2012
|
Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high-versus lower-risk rheumatoid arthritis patients.
Arthritis Care and Research.
64:1480-1489.
2012
|
|
| 2012
|
A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The treatment of early aggressive rheumatoid arthritis trial.
Arthritis and Rheumatism.
64:2824-2835.
2012
|
|
| 2012
|
Defining physiologically "normal" vitamin D in African Americans.
Osteoporosis International.
23:2283-2291.
2012
|
|
| 2012
|
Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy.
Arthritis Care and Research.
64:1282-1291.
2012
|
|
| 2012
|
Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment.
Arthritis and Rheumatism.
64:2773-2780.
2012
|
|
| 2012
|
Association between Vaccination for Herpes Zoster and Risk of Herpes Zoster Infection among Older Patients with Selected Immune-Mediated Diseases.
Journal of the American Medical Association.
308:43-49.
2012
|
|
| 2012
|
Management of osteoporosis among the elderly with other chronic medical conditions.
Drugs and Aging.
29:549-564.
2012
|
|
| 2012
|
Adherence with intravenous zoledronate and intravenous ibandronate in the United States medicare population.
Arthritis Care and Research.
64:1054-1060.
2012
|
|
| 2012
|
Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: A post-hoc analysis of the RAPID 1 trial.
Journal of Rheumatology.
39:1326-1333.
2012
|
|
| 2012
|
Association of intact parathyroid hormone levels with subsequent hip BMD loss: The Osteoporotic Fractures in Men (MrOS) study.
Journal of Clinical Endocrinology and Metabolism.
97:1937-1944.
2012
|
|
| 2012
|
Malignancy validation in a United States registry of rheumatoid arthritis patients.
BMC Musculoskeletal Disorders.
13.
2012
|
|
| 2012
|
Comparative safety of infliximab and etanercept on the risk of serious infections: Does the association vary by patient characteristics?.
Pharmacoepidemiology and Drug Safety.
21:524-534.
2012
|
|
| 2012
|
Direct healthcare costs of osteoporosis-related fractures in managed care patients receiving pharmacological osteoporosis therapy.
Applied Health Economics and Health Policy.
10:163-173.
2012
|
|
| 2012
|
Central DXA utilization shifts from office-based to hospital-based settings among medicare beneficiaries in the wake of reimbursement changes.
Journal of Bone and Mineral Research.
27:858-864.
2012
|
|
| 2012
|
Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases.
Arthritis Care and Research.
64:612-615.
2012
|
|
| 2012
|
Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendations.
Arthritis and Rheumatism.
64:630-638.
2012
|
|
| 2012
|
Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: The ROSE study.
Annals of the Rheumatic Diseases.
71:198-205.
2012
|
|
| 2012
|
In response
2012
|
|
| 2012
|
Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: Exploratory analyses from the TEMPO trial.
Annals of the Rheumatic Diseases.
71:206-212.
2012
|
|
| 2012
|
2012 update of the 2008 American college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.
Arthritis Care and Research.
64:625-639.
2012
|
|
| 2012
|
Evaluating comorbidity scores based on health service expenditures.
Health care financing review.
2.
2012
|
|
| 2012
|
Improving osteoporosis care in high-risk home health patients through a high-intensity intervention.
Contemporary Clinical Trials.
33:206-212.
2012
|
|
| 2012
|
Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan.
Bone.
50:870-875.
2012
|
|
| 2012
|
Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12 weeks associated with low disease activity at 1 year..
Arthritis Care and Research.
64:658-667.
2012
|
|
| 2012
|
Rates of malignancy associated with juvenile idiopathic arthritis and its treatment..
Arthritis and Rheumatism.
64:1263-1271.
2012
|
|
| 2012
|
Reply.
Arthritis Care and Research.
64:157-158.
2012
|
|
| 2012
|
Systematic Review of Tocilizumab for Rheumatoid Arthritis: A New Biologic Agent Targeting the Interleukin-6 Receptor
2012
|
|
| 2012
|
Validation of Diagnostic Codes for Subtrochanteric, Diaphyseal, and Atypical Femoral Fractures Using Administrative Claims Data.
Journal of Clinical Densitometry.
15:92-102.
2012
|
|
| 2011
|
Initiation of tumor necrosis factor-αantagonists and the risk of hospitalization for infection in patients with autoimmune diseases.
Journal of the American Medical Association.
306:2331-2339.
2011
|
|
| 2011
|
Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice.
Arthritis Care and Research.
63:1680-1690.
2011
|
|
| 2011
|
Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: A retrospective pooled analysis.
Rheumatology.
50:2223-2232.
2011
|
|
| 2011
|
Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: Experience from a large US cohort.
Arthritis Care and Research.
63:1672-1679.
2011
|
|
| 2011
|
Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems.
Pharmacoepidemiology and Drug Safety.
20:1199-1209.
2011
|
|
| 2011
|
Validation of ICD-9-CM codes to identify gastrointestinal perforation events in administrative claims data among hospitalized rheumatoid arthritis patients.
Pharmacoepidemiology and Drug Safety.
20:1150-1158.
2011
|
|
| 2011
|
The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: A longitudinal observational study.
Arthritis Research and Therapy.
13.
2011
|
|
| 2011
|
Changes in cotherapies after initiation of disease - Modifying antirheumatic drug therapy in patients with rheumatoid arthritis.
Arthritis Care and Research.
63:1415-1424.
2011
|
|
| 2011
|
Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis.
Arthritis Research and Therapy.
13.
2011
|
|
| 2011
|
Geographic distribution of endemic fungal infections among older persons, United States
2011
|
|
| 2011
|
Developing a construct to evaluate flares in rheumatoid arthritis: A conceptual report of the OMERACT RA Flare Definition Working Group.
Journal of Rheumatology.
38:1745-1750.
2011
|
|
| 2011
|
Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: An analysis of individual patient-level data.
Arthritis and Rheumatism.
63:2203-2208.
2011
|
|
| 2011
|
Erratum: Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research (Journal of Bone and Mineral Research (2010) 25 (2267-2294)).
Journal of Bone and Mineral Research.
26:1987.
2011
|
|
| 2011
|
Improving osteoporosis care through multimodal interventions: Insights from the University of Alabama at Birmingham Center for Education and Research on Therapeutics.
Osteoporosis International.
22.
2011
|
|
| 2011
|
Long-term safety concerns of antiresorptive therapy.
Rheumatic Disease Clinics of North America.
37:387-400.
2011
|
|
| 2011
|
The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents.
Annals of the Rheumatic Diseases.
70:1401-1406.
2011
|
|
| 2011
|
Consistency of knee pain and risk of knee replacement: The multicenter osteoarthritis study.
Journal of Rheumatology.
38:1390-1395.
2011
|
|
| 2011
|
Corrigendum to "Cost burden of second fracture in the US Health System" [Bone 48 (2011) 828-836].
Bone.
48:1429.
2011
|
|
| 2011
|
Medical costs of osteoporosis in the elderly Medicare population.
Osteoporosis International.
22:1835-1844.
2011
|
|
| 2011
|
Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: Post-hoc analysis of a randomized controlled trial.
Journal of Rheumatology.
38:990-996.
2011
|
|
| 2011
|
Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of Care
2011
|
|
| 2011
|
High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis.
Annals of the Rheumatic Diseases.
70:785-791.
2011
|
|
| 2011
|
Placebo adherence, clinical outcomes, and mortality in the women's health initiative randomized hormone therapy trials.
Medical Care.
49:427-435.
2011
|
|
| 2011
|
Response to Letter to Editor on validation study identifying bacterial infections in rheumatoid arthritis patients.
Journal of Clinical Epidemiology.
64:573.
2011
|
|
| 2011
|
Cost burden of second fracture in the US Health System.
Bone.
48:828-836.
2011
|
|
| 2011
|
Erratum: Clinical and demographic factors associated with fractures among older Americans (Osteoporosis International DOI: 10.1007/s00198-010-1300-8).
Osteoporosis International.
22:1275-1276.
2011
|
|
| 2011
|
The relationship between bisphosphonate adherence and fracture: Is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial.
Journal of Bone and Mineral Research.
26:683-688.
2011
|
|
| 2011
|
Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis.
Annals of the Rheumatic Diseases.
70:576-582.
2011
|
|
| 2011
|
TNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis.
Medicine.
90:139-145.
2011
|
|
| 2011
|
The incidence of gastrointestinal perforations among rheumatoid arthritis patients.
Arthritis and Rheumatism.
63:346-351.
2011
|
|
| 2011
|
Clinical and demographic factors associated with fractures among older Americans.
Osteoporosis International.
22:1263-1274.
2011
|
|
| 2011
|
Injection-site burning and stinging in patients with rheumatoid arthritis using injectable biologics.
Current Medical Research and Opinion.
27:71-78.
2011
|
|
| 2011
|
Official Positions for FRAX® Clinical Regarding International Differences. From Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.
Journal of Clinical Densitometry.
14:240-262.
2011
|
|
| 2011
|
Which fractures are most attributable to osteoporosis?.
Journal of Clinical Epidemiology.
64:46-53.
2011
|
|
| 2010
|
Predicting hip and major osteoporotic fractures using administrative data.
JAMA Internal Medicine.
170:1940-1942.
2010
|
|
| 2010
|
Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research.
Journal of Bone and Mineral Research.
25:2267-2294.
2010
|
|
| 2010
|
Explaining the cardiovascular risk associated with rheumatoid arthritis: Traditional risk factors versus markers of rheumatoid arthritis severity.
Annals of the Rheumatic Diseases.
69:1920-1925.
2010
|
|
| 2010
|
Consistency of knee pain: Correlates and association with function.
Osteoarthritis and Cartilage.
18:1250-1255.
2010
|
|
| 2010
|
Converting modified Health Assessment Questionnaire (HAQ), multidimensional HAQ, and HAQII scores into original HAQ scores using models developed with a large cohort of rheumatoid arthritis patients.
Arthritis Care and Research.
62:1481-1488.
2010
|
|
| 2010
|
Osteoporosis care in the United States after declines in reimbursements for DXA.
Journal of Clinical Densitometry.
13:352-360.
2010
|
|
| 2010
|
Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis.
Osteoporosis International.
21:1573-1584.
2010
|
|
| 2010
|
Health services utilization after fractures: Evidence from Medicare
2010
|
|
| 2010
|
Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis.
Annals of the Rheumatic Diseases.
69:1612-1617.
2010
|
|
| 2010
|
The delivery of evidence-based preventive care for older Americans with arthritis.
Arthritis Research and Therapy.
12.
2010
|
|
| 2010
|
Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US national osteoporosis foundation guidelines.
Journal of Bone and Mineral Research.
25:1506-1511.
2010
|
|
| 2010
|
Identifying types of nursing facility stays using medicare claims data: An algorithm and validation
2010
|
|
| 2010
|
Privacy-maintaining propensity score-based pooling of multiple databases applied to a study of biologics.
Medical Care.
48.
2010
|
|
| 2010
|
Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: A review of the literature and a case report
2010
|
|
| 2010
|
Pre-radiographic MRI findings are associated with onset of knee symptoms: the most study.
Osteoarthritis and Cartilage.
18:323-328.
2010
|
|
| 2010
|
Vitamin D status and its associations with disease activity and severity in african americans with recent-onset rheumatoid arthritis.
Journal of Rheumatology.
37:275-281.
2010
|
|
| 2010
|
Physician preference motivates the use of anti-tumor necrosis factor therapy independent of clinical disease activity.
Arthritis Care and Research.
62:101-107.
2010
|
|
| 2010
|
A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis Registries1.
Seminars in Arthritis and Rheumatism.
40:2-14.e1.
2010
|
|
| 2010
|
American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis..
Arthritis Care and Research.
62:1515-1526.
2010
|
|
| 2010
|
Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide.
Annals of the Rheumatic Diseases.
69:43-47.
2010
|
|
| 2010
|
High systemic bone mineral density increases the risk of incident knee OA and joint space narrowing, but not radiographic progression of existing knee OA: The MOST study.
Annals of the Rheumatic Diseases.
69:163-168.
2010
|
|
| 2010
|
Is withholding osteoporosis medication after fracture sometimes rational? A Comparison of the risk for second fracture versus death
2010
|
|
| 2009
|
Health care expenditures associated with skeletal fractures among medicare beneficiaries, 1999-2005.
Journal of Bone and Mineral Research.
24:2050-2055.
2009
|
|
| 2009
|
"pathologic" fractures: Should these be included in epidemiologic studies of osteoporotic fractures?.
Osteoporosis International.
20:1969-1972.
2009
|
|
| 2009
|
Do physicians within the same practice setting manage osteoporosis patients similarly? Implications for implementation research.
Osteoporosis International.
20:1921-1927.
2009
|
|
| 2009
|
Skeletal health among African Americans with recent-onset rheumatoid arthritis.
Arthritis and Rheumatism.
61:1379-1386.
2009
|
|
| 2009
|
Quality health care gaps in osteoporosis: How can patients, providers, and the health system do a better job?.
Current Osteoporosis Reports.
7:27-34.
2009
|
|
| 2009
|
Systemic Nonarticular Manifestations of Rheumatoid Arthritis: Focus on Inflammatory Mechanisms.
Seminars in Arthritis and Rheumatism.
39:132-143.
2009
|
|
| 2009
|
Estimated prevalence and patterns of presumed osteoporosis among older Americans based on Medicare data.
Osteoporosis International.
20:1507-1515.
2009
|
|
| 2009
|
The geographic availability and associated utilization of dual-energy X-ray absorptiometry (DXA) testing among older persons in the United States.
Osteoporosis International.
20:1553-1561.
2009
|
|
| 2009
|
Adherence to osteoporosis treatments: Room for improvement.
Current Opinion in Rheumatology.
21:356-362.
2009
|
|
| 2009
|
RisedronatE and ALendronate intervention over three years (REALITY): Minimal differences in fracture risk reduction.
Osteoporosis International.
20:973-978.
2009
|
|
| 2009
|
Vertebroplasty and kyphoplasty are associated with an increased risk of secondary vertebral compression fractures: A population-based cohort study.
Osteoporosis International.
20:819-826.
2009
|
|
| 2009
|
Management of osteoporosis among home health and long-term care patients with a prior fracture.
Southern Medical Journal.
102:397-404.
2009
|
|
| 2009
|
Improving the prediction of medication compliance: The example of bisphosphonates for osteoporosis.
Medical Care.
47:334-341.
2009
|
|
| 2009
|
Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients.
Journal of Clinical Epidemiology.
62.
2009
|
|
| 2009
|
Bridging the osteoporosis quality chasm.
Journal of Bone and Mineral Research.
24:3-7.
2009
|
|
| 2009
|
Identification and validation of vertebral compression fractures using administrative claims data.
Medical Care.
47:69-72.
2009
|
|
| 2009
|
Population-based fracture risk assessment and osteoporosis treatment disparities by race and gender.
Journal of General Internal Medicine.
24:956-962.
2009
|
|
| 2009
|
Validity of physician-reported hospitalized infections in a US arthritis registry..
Rheumatology.
48:1269-1272.
2009
|
|
| 2008
|
Tumor necrosis factor inhibitors and infection complications.
Current Rheumatology Reports.
10:383-389.
2008
|
|
| 2008
|
Risk of hip fracture after bisphosphonate discontinuation: Implications for a drug holiday.
Osteoporosis International.
19:1613-1620.
2008
|
|
| 2008
|
Muscle Mass Is More Strongly Related to Hip Bone Mineral Density Than Is Quadriceps Strength or Lower Activity Level in Adults Over Age 50 Year.
Journal of Clinical Densitometry.
11:503-510.
2008
|
|
| 2008
|
Regional Variation in the Denial of Reimbursement for Bone Mineral Density Testing Among US Medicare Beneficiaries.
Journal of Clinical Densitometry.
11:568-574.
2008
|
|
| 2008
|
Adaptation of bayesian data mining algorithms to longitudinal claims data: Coxib safety as an example.
Medical Care.
46:969-975.
2008
|
|
| 2008
|
Benefit of adherence with bisphosphonates depends on age and fracture type: Results from an analysis of 101,038 new bisphosphonate users.
Journal of Bone and Mineral Research.
23:1435-1441.
2008
|
|
| 2008
|
Mortality and osteoporotic fractures: Is the link causal, and is it modifiable?.
Clinical and Experimental Rheumatology.
26.
2008
|
|
| 2008
|
Longitudinal trends in use of bone mass measurement among older Americans, 1999-2005.
Journal of Bone and Mineral Research.
23:1061-1067.
2008
|
|
| 2008
|
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.
Arthritis and Rheumatism.
59:762-784.
2008
|
|
| 2008
|
Leg-length inequality is not associated with greater trochanteric pain syndrome.
Arthritis Research and Therapy.
10.
2008
|
|
| 2008
|
Association of infections and tuberculosis with antitumor necrosis factor alpha therapy.
Current Opinion in Rheumatology.
20:320-326.
2008
|
|
| 2008
|
Biologics and heart failure in rheumatoid arthritis: Are we any wiser?.
Current Opinion in Rheumatology.
20:327-333.
2008
|
|
| 2008
|
Improving quality of care in osteoporosis: Opportunities and challenges.
Current Rheumatology Reports.
10:123-130.
2008
|
|
| 2008
|
The epidemiology of glucocorticoid-associated adverse events.
Current Opinion in Rheumatology.
20:131-137.
2008
|
|
| 2008
|
Association of health-related quality of life with dual use of prescription and over-the-counter nonsteroidal antiinflammatory drugs.
Arthritis and Rheumatism.
59:227-233.
2008
|
|
| 2008
|
Mortality and osteoporotic fractures: is the link causal, and is it modifiable?.
Clinical and Experimental Rheumatology.
26:S125-S137.
2008
|
|
| 2007
|
Racial/ethnic disparities in patient-reported nonsteroidal antiinflammatory drug (NSAID) risk awareness, patient-doctor NSAID risk communication, and NSAID risk behavior.
Arthritis and Rheumatism.
57:1539-1545.
2007
|
|
| 2007
|
Challenges in defining and improving osteoporosis quality of care.
Clinical and Experimental Rheumatology.
25.
2007
|
|
| 2007
|
Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor α antagonists.
Arthritis and Rheumatism.
56:4226-4227.
2007
|
|
| 2007
|
Randomized Trial to Improve Fracture Prevention in Nursing Home Residents.
American Journal of Medicine.
120:886-892.
2007
|
|
| 2007
|
Greater Trochanteric Pain Syndrome: Epidemiology and Associated Factors.
Archives of Physical Medicine and Rehabilitation.
88:988-992.
2007
|
|
| 2007
|
Prevalence and predictors of osteoporosis treatment in nursing home residents with known osteoporosis or recent fracture.
Osteoporosis International.
18:553-559.
2007
|
|
| 2007
|
Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists.
Arthritis and Rheumatism.
56:1125-1133.
2007
|
|
| 2007
|
Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users: A prospective randomized trial.
JAMA Internal Medicine.
167:591-596.
2007
|
|
| 2007
|
Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor α antagonists and disease-modifying antirheumatic drugs.
Arthritis and Rheumatism.
57:343-346.
2007
|
|
| 2007
|
Prevention and treatment of glucocorticoid-induced osteoporosis.
Current Osteoporosis Reports.
5:14-21.
2007
|
|
| 2007
|
Challenges in defining and improving osteoporosis quality of care..
Clinical and Experimental Rheumatology.
25:142-146.
2007
|
|
| 2007
|
Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-α antagonists.
Rheumatology.
46:1688-1693.
2007
|
|
| 2006
|
Osteoporosis in the home health care setting: A window of opportunity?.
Arthritis and Rheumatism.
55:971-975.
2006
|
|
| 2006
|
Treatment of rheumatoid arthritis.
American Journal of Health-System Pharmacy.
63:2451-2465.
2006
|
|
| 2006
|
Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users.
Pharmacoepidemiology and Drug Safety.
15:710-718.
2006
|
|
| 2006
|
Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs.
American Journal of Health-System Pharmacy.
63:1837-1851.
2006
|
|
| 2006
|
Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users.
Osteoporosis International.
17:1268-1274.
2006
|
|
| 2006
|
Trends in prevention of glucocorticoid-induced osteoporosis.
Journal of Rheumatology.
33:1651-1657.
2006
|
|
| 2006
|
Population-based assessment of adverse events associated with long-term glucocorticoid use.
Arthritis and Rheumatism.
55:420-426.
2006
|
|
| 2006
|
Medication errors with the use of allopurinol and colchicine: A retrospective study of a national, anonymous internet-accessible error reporting system.
Journal of Rheumatology.
33:562-566.
2006
|
|
| 2006
|
Ethnic variations in the prevalence of metabolic bone disease among HIV-positive patients with lipodystrophy.
AIDS Research and Human Retroviruses.
22:125-131.
2006
|
|
| 2006
|
Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventions.
Pharmacoepidemiology and Drug Safety.
15:11-18.
2006
|
|
| 2005
|
A group randomized trial to improve safe use of nonsteroidal anti-inflammatory drugs.
American Journal of Managed Care.
11:537-543.
2005
|
|
| 2005
|
Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients.
Arthritis and Rheumatism.
52:2485-2494.
2005
|
|
| 2005
|
Prevalence of osteoporosis and osteopenia among African Americans with early rheumatoid arthritis: The impact of ethnic-specific normative data.
Journal of the National Medical Association.
97:1155-1160.
2005
|
|
| 2004
|
Swallowing difficulties from "DISH-phagia".
Journal of Rheumatology.
31:2526-2527.
2004
|
|
| 2004
|
Evaluating and improving the quality of care in rheumatic disease
2004
|
|
| 2004
|
Vitamin D Intake Is Inversely Associated With Rheumatoid Arthritis: Results From the Iowa Women's Health Study.
Arthritis and Rheumatism.
50:72-77.
2004
|
|
| 2003
|
Nonsteroidal Antiinflammatory Drug Toxicity Monitoring and Safety Practices.
Journal of Rheumatology.
30:2680-2688.
2003
|
|
| 2003
|
The Use of Glucocorticoids in Arthritis – 20 Clinical Pearls.
The Journal of musculoskeletal medicine.
20:425-433.
2003
|
|
| 1985
|
Reply.
American Journal of Ophthalmology.
99:220.
1985
|
|
